Samarium-153-ethylene diamine tetramethylene phosphonate, a beta-emitting bone-targeted radiopharmaceutical, useful for patients with osteoblastic bone metastases

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 235-242

  Longo, John ^a   Lutz, Stephen ^b   Johnstone, Candice ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b Blanchard Valley Regional Cancer Center   (United States)

Author keywords

Bone metastases; Pain; Pain flare; Radiopharmaceuticals

Indexed keywords

DOCETAXEL; ESTRAMUSTINE; LEXIDRONAM SAMARIUM SM 153; PLACEBO;

ANEMIA; ANOREXIA; BETA RADIATION; BLOOD TOXICITY; BONE METASTASIS; CARDIOVASCULAR DISEASE; CONSTIPATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; DYSPNEA; FEVER; HUMAN; LEUKOPENIA; LIVER TOXICITY; MULTICENTER STUDY (TOPIC); MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHUMAN; PALLIATIVE THERAPY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT DISEASE; REVIEW; SPINAL CORD COMPRESSION; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

EID: 84881541048     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S35789     Document Type: Review

References (33)

1. Hartsell WF, Yajnik S. Palliation of bone metastases. In: Halperin EC, Perez CA, Brady LW, et al, editors. Perez and Brady's Principles and Practice of Radiation Oncology, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008:1986-1999.
2. Sartor O. Overview of samarium-153 lexidronam in the treatment of painful metastatic bone disease. Rev Urol. 2004;6 Suppl 10:S3-S12.
3. Janjan N, Lutz ST, Bedwinek JM, et al. Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology. J Palliat Med. 2009;12(5):417-426.
4. Lutz S, Berk L, Chang E, et al. Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys. 2011;79(4):965-976.
5. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology - prostate cancer. Version 2. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed July 1, 2013.
6. Bauman G, Charette M, Reid R, Sathya J. Radiopharmaceuticals for the palliation of painful bone metastasis: a systemic review. Radiother Oncol. 2005;75(3):258-270.
7. Chiacchio S, Mazzarri S, Lorenzoni A, et al. Radionuclide therapy and integrated protocols for bone metastases. Q J Nucl Med Mol Imaging. 2011;55(4):431-447.
8. Finlay IG, Mason MD, Shelley M. Radioisotopes for the palliation of metastatic bone cancer: a systematic review. Lancet Oncol. 2005;6(6):392-400.
9. Sartor O, Reid RH, Hoskin PJ, et al. Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology. 2004;63(5):940-945.
10. McEwan AJ. Use of radionuclides for the palliation of bone metastases. Semin Radiat Oncol. 2000;10(2):103-114.
11. Tian JH, Zhang JM, Hou QT, et al. Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China. Eur J Nucl Med. 1999;26(1):2-7.
12. Vengalil S, O'Sullivan JM, Parker CC. Use of radionuclides in metastatic prostate cancer: pain relief and beyond. Curr Opin Support Palliat Care. 2012;6(3):310-315.
13. Class R, Jost M, Mose S, et al. Radioimmunoglobulins and nonsealed radionuclide therapy. In: Halperin EC, Perez CA, Brady LW, et al, editors. Perez and Brady's Principles and Practice of Radiation Oncology, 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2008: 583-598.
14. National Cancer Institute. FDA approval for radium 223 dichloride. 2013. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-radium-223-dichloride. Accessed June 15, 2013.
15. Nilsson S, Strang B, Aksnes AK, et al. A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. Eur J Cancer. 2012;48(5):678-686.
16. Nilsson S, Franzén L, Parker C, et al. Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases. Clin Genitourin Cancer. 2013;11(1):20-26.
17. Parker C, Nilsson S, Heinrich D, et al. Updated analysis of the phase III, double-blind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J Clin Oncol. 2012;30 Suppl:LBA4512.
18. Eary J, Collins C, Stabin M, et al. Samarium-153-EDTMP biodistribution and dosimetry estimation. J Nucl Med. 1993;34(7):1031-1036.
19. Resche I, Chatal JF, Pecking A, et al. A dose-controlled study of 153Smethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases. Eur J Cancer. 1997;33(10): 1583-1591.
20. Serafini AN. Samarium Sm-153 lexidronam for the palliation of bone pain associated with metastases. Cancer. 2000;88(Suppl 12): 2934-2939.
21. Serafini AN, Houston SJ, Resche I, et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a doubleblind placebo-controlled clinical trial. J Clin Oncol. 1998;16(4): 1574-1581.
22. Sartor O, Reid RH, Bushnell DL, Quick DP, Ell PJ. Safety and efficacy of repeat administration of samarium Sm-153 lexidronam to patients with metastatic bone pain. Cancer. 2007;109(3):637-643.
23. Fizazi K, Benzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration resistant prostate cancer. J Clin Oncol. 2009;27(15): 2429-2435.
24. 153Sm-lexidronam in patients with castration-resistant metastatic prostate cancer. Urol Oncol. 2009;29(6):670-675.
25. Morris MJ, Pandit-Taskar N, Carrasquillo J, et al. Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer. J Clin Oncol. 2009;27(15):2436-2442.
26. Roqué I Figuls M,Martinez-Zapata MJ,Scott-Brown M,Alonso-Coello P. Radioisotopes for metastatic bone pain. Cochrane Database Syst Rev. 2011;(7):CD003347.
27. Anderson PM, Wiseman GA, Dispenzieri A, et al. High dose samarium 153 ethylene diamine tetramethylene phophonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20(1):189-196.
28. 153Samarium-EDTMP administration followed by hematopoietic stem cell support for bone metastases in osteosarcoma patients. Ann Oncol. 2012;23(7): 1899-1905.
29. Lattimer JC, Corwin LA, Stapleton J, et al. Clinical and clinicopathologic effects of samarium-153-EDTMP administered intravenously to normal beagle dogs. J Nucl Med. 1990;31(5):586-593.
30. Lattimer JC, Corwin LA, Stapleton J, et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J Nucl Med. 1990;31(8):1316-1325.
31. Singh A, Holmes RA, Farhangi M, et al. Human pharmacokinetics of samarium-153 EDTMP in metastatic cancer. J Nucl Med. 1989;30(11): 1814-1818.
32. Farhanghi M, Holmes RA, Volkert WA, Logan W, Singh Amolak. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33(8):1451-1458.
33. Collins C, Eary JF, Donaldson G, et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med. 1993;34(11):1839-1844.